Jamie Iain Campbell

This inventor holds 27 USPTO granted patents and 19 published patent applications and 5 EPO patents, primarily in Immunotherapy Antibodies. Top assignees: Kymab Limited, Medimmune Limited, F-Star Therapeutics, Inc.. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jamie Iain Campbell. Retrieved from https://idiyas.com/inventor/jamie-iain-campbell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 19)

% Patents Active = 92.6

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 5.8

ph-index = 10

Forward Citations = 332(Granted Patents)

Location History:

Cambridgeshire, GB (2012 - 2014)
Cambridge, GB (2015 - 2024)

Company Filing History:

F-Star Therapeutics, Inc.

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Anti-OX40L Antibodies

PD-L1 Antibodies

Cytokines

Bispecific Antibodies

Nucleic Acids

Immunocytokines

Graft Versus Host Disease

Synergistic Combinations

IL-1R1 Antibodies

Binding Molecules

Treatment Methods

Anti-ICOS Antibodies

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50880 - Anti-Human OX40L Antibodies and Methods of Treatment (2026-05-05),

2. 12209128 - Anti-PD-L1 antibodies (2025-01-28),

3. 11965026 - Anti-PD-L1 and IL-2 cytokines (2024-04-23),

4. 11858996 - Anti-ICOS antibodies (2024-01-02),

5. 11773175 - Antibodies, uses and methods (2023-10-03),

6. 11753479 - Nucleic acids encoding anti-OX40L antibodies (2023-09-12),

7. 11629189 - Bispecific antibody for ICOS and PD-L1 (2023-04-18),

8. 11440960 - TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo (2022-09-13),

9. 11396550 - Methods of treating comprising administering anti-OX40L antibodies (2022-07-26),

10. 11214620 - Binding molecules binding PD-L1 and LAG-3 (2022-01-04),

11. 10669342 - Anti-OX40L antibodies and methods of treating graft versus host disease (2020-06-02),

12. 10654935 - Methods of treating SLE with anti-OX40L antibodies (2020-05-19),

13. 10604576 - Antibodies and immunocytokines (2020-03-31),

14. 10259880 - Anti-LIGHT antibodies (2019-04-16),

15. 9957323 - Anti-ICOS antibodies (2018-05-01),

Title: Jamie Iain Campbell: Innovator in Anti-PD-L1 Antibodies

Introduction

Jamie Iain Campbell, based in Cambridgeshire, GB, is a prolific inventor known for his significant contributions to the field of biotechnology. With a remarkable portfolio of 26 patents, Campbell has demonstrated his expertise and dedication to innovation in medical treatments.

Latest Patents

Among his most recent inventions are the anti-PD-L1 antibodies. This invention encompasses not only anti-PD-L1 antibodies but also bispecific antibodies containing a domain specifically targeting PD-L1, as well as immunocytokines that consist of an anti-PD-L1 antibody fused to a cytokine such as IL-2. The invention further outlines methods of treatment, uses, and pharmaceutical compositions that incorporate these antibodies, bispecific antibodies, and immunocytokines.

Career Highlights

Jamie Iain Campbell has held a key role in advancing therapeutic innovations through his work with prestigious organizations. He has collaborated with Kymab Limited and MedImmune Limited, where he applied his knowledge to develop groundbreaking medical solutions.

Collaborations

Throughout his career, Campbell has worked alongside esteemed colleagues, including Ian Kirby and Miha Kosmac, fostering an environment of collaboration that has undoubtedly driven many of his innovations forward.

Conclusion

Jamie Iain Campbell's work, particularly on anti-PD-L1 antibodies, highlights his commitment to enhancing treatment methodologies in the biopharmaceutical landscape. His extensive experience and impressive patent portfolio underscore his status as a valuable contributor to the field of biotechnology.

Profile summary based on public USPTO records.